Scleroderma (Systemic Sclerosis) Pathophysiology Explained

Added:

The Fetal Microchimerism Hypothesis

While traditional pathophysiological models depict systemic sclerosis (SSc) as a primary autoimmune disorder driven by endogenous immune dysfunction, the Fetal Microchimerism Hypothesis offers a compelling alternative etiology. This theory proposes that SSc, which predominantly affects women, is triggered by the long-term persistence of foreign fetal cells in the maternal circulation (or maternal cells in the offspring) decades after pregnancy. These persistent allogeneic cells are thought to initiate a low-grade, chronic graft-versus-host-like reaction, resulting in the characteristic vascular damage, immune activation, and widespread fibrosis. This perspective challenges the conventional 'self-versus-non-self' autoimmune paradigm by suggesting that SSc may actually be an alloimmune response to foreign cellular remnants, potentially shifting how researchers approach the disease's triggers and immunomodulatory therapies.

Basic immunology, including the mechanisms of autoimmunity, self-tolerance, and the role of autoantibodies in tissue damage.
The structure and function of connective tissue, specifically the role of fibroblasts, collagen synthesis, and the extracellular matrix.
Vascular physiology, focusing on endothelial cell dysfunction, vasospasm mechanisms, and the physiology of Raynaud's phenomenon.
General concepts of chronic inflammation and the pathological progression from tissue injury to fibrosis (scarring).
Advanced management of Scleroderma Renal Crisis (SRC), including the specific role of ACE inhibitors and avoidance of high-dose corticosteroids.
Detailed study of Pulmonary Arterial Hypertension (PAH) screening, diagnosis (via right heart catheterization), and targeted vasodilator therapies.
Differential diagnosis of systemic autoimmune rheumatic diseases, comparing systemic sclerosis with Mixed Connective Tissue Disease (MCTD) and Systemic Lupus Erythematosus (SLE).
Emerging biological therapies and clinical trials targeting specific fibrotic pathways, such as TGF-beta inhibition or autologous hematopoietic stem cell transplantation (HSCT).
168.2K views2.5Klikes14:32@drandrasfazakasOriginal Release: 2014-03-16

Systemic sclerosis (scleroderma) is an autoimmune disease primarily affecting middle-aged women, characterized by abnormal activation of CD4 T-helper lymphocytes that release cytokines causing vascular injury and excessive collagen production by activated fibroblasts, leading to widespread fibrosis affecting the skin (causing thickening, tightness, and Raynaud's phenomenon), gastrointestinal tract (esophageal dysmotility, dysphagia), heart (myocardial fibrosis, cardiomyopathy), lungs (pulmonary hypertension, interstitial fibrosis), kidneys (potentially fatal scleroderma crisis), and musculoskeletal system; treatment focuses on managing symptoms through vasodilators, immunosuppressants, and supportive care while monitoring for life-threatening complications.